Gland, Switzerland | 15.05.2022 – Kainjoo SA and OM Pharma SA have reaffirmed and expanded their strategic collaboration by entering into a Master Service Agreement (MSA). Initially centred on OM Pharma’s Swiss affiliate, this new agreement extends the partnership to global operations, strengthening shared efforts to enhance marketing performance and operational capabilities through brand technologies.
The renewed engagement positions Kainjoo as a transformation partner for OM Pharma’s regional and global teams, enabling compliant, AI-powered, and scalable marketing platforms across multiple regulated markets.
Key Highlights
- Enhancement of Veeva CRM with multichannel e-detailers and sponsored rep emails to boost field force engagement
- Launch of persona-based advertising trading desk for Broncho-Vaxom® campaigns, increasing digital campaign precision
- Deployment of AI-driven web factories supporting multilingual, compliant HCP portals integrated with SwissRX
Kainjoo’s role in OM Pharma’s transformation journey began with the implementation of a headless, multisite web factory platform. This infrastructure enables the rapid deployment of affiliate websites across multiple languages while maintaining regulatory compliance, aligning with Switzerland’s new Federal Data Protection Act (nFADP). The system provides a centralised yet flexible approach to digital asset management and campaign orchestration.
“We’re now able to spin off a website in multiple languages thanks to AI and run it through our Medical Legal Reviews much faster,” explains Evelyne Filip, Digital Head at OM Pharma Switzerland. “This gives us a reliable framework to scale HCP engagement while staying aligned with local and international standards.”
The digital footprint was further strengthened through the configuration of Veeva CRM modules, enabling customer-facing teams with sponsored rep emails and e-detailing content built using Kainjoo’s proprietary Online Learning Moments framework. These e-detailers are designed as immersive, multichannel stories that extend across emails, microsites, and face-to-face interactions, supporting a seamless customer experience.
Campaign delivery has also evolved with the launch of a persona-based advertising trading desk focused on Broncho-Vaxom®, OM Pharma’s flagship immunostimulant. The system dynamically targets healthcare professionals with personalised messages, improving both reach and engagement while providing measurable performance insights.
“We love working with OM, as this is the definition of a true partnership,” says Haider Alleg, founder at Kainjoo and principal for the OM Pharma account. “We innovate together and co-create at every stage. The experience and trust we’ve built allow us to move faster and deliver outcomes that truly matter to the business.”
Through this agreement, OM Pharma gains access to Kainjoo’s full-service capabilities—spanning brand-tech specialists, engineering teams, and campaign experts—enabling regional and global units to streamline commercial operations, reduce time to market, and scale with confidence. With over 50 codes and compliance frameworks mastered, Kainjoo offers a robust foundation for future-proofing marketing ecosystems in highly regulated sectors.
About OM Pharma
OM Pharma is a global, Geneva-based biopharmaceutical company specialized in the prevention of recurrent respiratory and urinary tract infections, as well as the treatment of vascular diseases. With a focus on improving patient outcomes, OM Pharma combines scientific expertise with a commitment to therapeutic innovation.
About Kainjoo
Kainjoo is a Swiss-originated, global brand-tech firm that supports the AI-first transformation of commercial operations in regulated industries. Known for its structured approach based on Japanese methodologies like Kaizen and Six Sigma, Kainjoo enables pharmaceutical companies to build, scale, and manage global brands through strategy, technology, and compliance-led execution.
Press Contact
Orsen Okami
Chief Business Officer
press@kainjoo.com
+41 21 561 34 96
press.kainjoo.com
